» Articles » PMID: 10973385

Adenocarcinoma of the Esophagogastric Junction: Results of Surgical Therapy Based on Anatomical/topographic Classification in 1,002 Consecutive Patients

Overview
Journal Ann Surg
Specialty General Surgery
Date 2000 Sep 6
PMID 10973385
Citations 230
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To assess the outcome of surgical therapy based on a topographic/anatomical classification of adenocarcinoma of the esophagogastric junction.

Summary Background Data: Because of its borderline location between the stomach and esophagus, the choice of surgical strategy for patients with adenocarcinoma of the esophagogastric junction is controversial.

Methods: In a large single-center series of 1,002 consecutive patients with adenocarcinoma of the esophagogastric junction, the choice of surgical approach was based on the location of the tumor center or tumor mass. Treatment of choice was esophagectomy for type I tumors (adenocarcinoma of the distal esophagus) and extended gastrectomy for type II tumors (true carcinoma of the cardia) and type III tumors (subcardial gastric cancer infiltrating the distal esophagus). Demographic data, morphologic and histopathologic tumor characteristics, and long-term survival rates were compared among the three tumor types, focusing on the pattern of lymphatic spread, the outcome of surgery, and prognostic factors in patients with type II tumors.

Results: There were marked differences in sex distribution, associated intestinal metaplasia in the esophagus, tumor grading, tumor growth pattern, and stage distribution between the three tumor types. The postoperative death rate was higher after esophagectomy than extended total gastrectomy. On multivariate analysis, a complete tumor resection (R0 resection) and the lymph node status (pN0) were the dominating independent prognostic factors for the entire patient population and in the three tumor types, irrespective of the surgical approach. In patients with type II tumors, the pattern of lymphatic spread was primarily directed toward the paracardial, lesser curvature, and left gastric artery nodes; esophagectomy offered no survival benefit over extended gastrectomy in these patients.

Conclusion: The classification of adenocarcinomas of the esophagogastric junction into type I, II, and III tumors shows marked differences between the tumor types and provides a useful tool for selecting the surgical approach. For patients with type II tumors, esophagectomy offers no advantage over extended gastrectomy if a complete tumor resection can be achieved.

Citing Articles

Current Standards and Controversies in Multidisciplinary Management of Locoregional Gastroesophageal Junction Tumors.

Santos E, Baig D, Sanford N Curr Oncol Rep. 2024; 26(12):1606-1611.

PMID: 39508985 DOI: 10.1007/s11912-024-01606-6.


mA modification enhances the stability of promotes tumorigenicity of esophagogastric junction adenocarcinoma via cell cycle.

Pan Y, Feng H, Zhou J, Zhang W, Liu Y, Zheng J Int J Biol Sci. 2024; 20(11):4209-4221.

PMID: 39247830 PMC: 11379066. DOI: 10.7150/ijbs.98535.


PERIOPERATIVE CHEMOTHERAPY, ADJUVANT CHEMOTHERAPY AND ADJUVANT CHEMORADIOTHERAPY IN THE SURGICAL TREATMENT OF GASTRIC CANCER IN A HOSPITAL OF THE BRAZILIAN UNIFIED HEALTH SYSTEM.

Pracucho E, Zanatto R, de Oliveira J, Lopes L Arq Bras Cir Dig. 2024; 37:e1810.

PMID: 38958346 PMC: 11216411. DOI: 10.1590/0102-6720202400017e1810.


Genomic Landscape of Adenocarcinomas Across the Gastroesophageal Junction: Moving on from the Siewert Classification.

Nakauchi M, Walch H, Nussenzweig S, Carr R, Vos E, Berger M Ann Surg. 2024; .

PMID: 38841851 PMC: 11621229. DOI: 10.1097/SLA.0000000000006363.


Surgical and Perioperative Treatments for Esophagogastric Junction Cancer.

Yanagimoto Y, Kurokawa Y, Doki Y Ann Thorac Cardiovasc Surg. 2024; 30(1).

PMID: 38839368 PMC: 11196162. DOI: 10.5761/atcs.ra.24-00056.


References
1.
Stark S, Romberg M, Pierce G, HERMRECK A, JEWELL W, MORAN J . Transhiatal versus transthoracic esophagectomy for adenocarcinoma of the distal esophagus and cardia. Am J Surg. 1996; 172(5):478-81; discussion 481-2. DOI: 10.1016/S0002-9610(96)00224-3. View

2.
Harrison L, Karpeh M, Brennan M . Proximal gastric cancers resected via a transabdominal-only approach. Results and comparisons to distal adenocarcinoma of the stomach. Ann Surg. 1997; 225(6):678-83; discussion 683-5. PMC: 1190868. DOI: 10.1097/00000658-199706000-00005. View

3.
Siewert J, Stein H, Sendler A, Fink U . Surgical resection for cancer of the cardia. Semin Surg Oncol. 1999; 17(2):125-31. DOI: 10.1002/(sici)1098-2388(199909)17:2<125::aid-ssu7>3.0.co;2-9. View

4.
Aikou T, Shimazu H . Difference in main lymphatic pathways from the lower esophagus and gastric cardia. Jpn J Surg. 1989; 19(3):290-5. DOI: 10.1007/BF02471404. View

5.
Steup W, De Leyn P, Deneffe G, Van Raemdonck D, Coosemans W, Lerut T . Tumors of the esophagogastric junction. Long-term survival in relation to the pattern of lymph node metastasis and a critical analysis of the accuracy or inaccuracy of pTNM classification. J Thorac Cardiovasc Surg. 1996; 111(1):85-94; discussion 94-5. DOI: 10.1016/S0022-5223(96)70404-X. View